Editorial policy
Corrections + editorial revisions log
Material corrections to GLP1Zoom content are logged here with the date they were made. Typos, design changes and new content are not logged — only factual inaccuracies, pricing errors, citation corrections, and unsupported claims about providers, drugs or us.
Report an error
Email editors@glp1zoom.com or use the contact form. If we confirm a material error, the correction is listed below with its date.
Logged corrections
Comparison pages and drug cards → Error: Comparison pages ranked drugs on weight loss using figures that were not theirs: Trulicity, Byetta and Bydureon BCise were given a class-average placeholder ("12% at 68 weeks, trial: class average"). Drug cards across the site listed a "trial average weight loss" for every brand, including 14.9% for Ozempic (the Wegovy trial result), 21% for Mounjaro and figures for Victoza, Trulicity, Byetta and Bydureon BCise from no trial of theirs. Comparison FAQs also said side-effect rates were comparable without figures.
Correction: Comparisons and cards now show a weight-loss figure only for drugs with their own trial, say so when a drug has none, and compare nausea using each label's placebo-controlled table.
Reported by: GLP1Zoom editorial audit
Rybelsus how-to guides → Error: Rybelsus had four how-to guides written for injectable pens: "How to Inject Rybelsus" listed a pen needle and alcohol swab, and the storage, disposal and travel guides described refrigeration, needles and a cold chain. Rybelsus is a tablet stored at room temperature.
Correction: The four Rybelsus how-to pages were removed and now return 404. How to take and store Rybelsus is on its dosage and storage pages, which describe the tablet.
Reported by: GLP1Zoom editorial audit
How-long-to-work, weight-loss, foods and hair-loss pages → Error: The how-long-to-work pages quoted weight loss "in clinical trials" for drugs whose trials did not measure it that way: Trulicity "0.0% by week 4 and 5.0% by week 12" came from a class-average placeholder, Mounjaro's figures came from the Zepbound obesity trial and Victoza's from the Saxenda trial. These pages and the weight-loss pages also gave a "5% by 12-16 weeks" benchmark, response predictors and comparison figures that we could not source, and the hair-loss answers on every drug's page quoted Wegovy's and Zepbound's rates.
Correction: Timelines now come from each label's dose schedule and, where the label states them, its steady-state timing and stopping rule (Saxenda: at least 4% loss by week 16). Weight-loss figures appear only for drugs with their own trial. The class-wide explanations moved to the GLP-1 hub pages, and each drug's hair-loss answer is its own label's.
Reported by: GLP1Zoom editorial audit
Drug pages (Victoza, Mounjaro, Ozempic, Zepbound) → Error: The Victoza page and its dosing calendar showed Saxenda's dose ladder up to 3 mg a day, although Victoza's maximum is 1.8 mg, and presented Saxenda's SCALE trial (8% weight loss) as a Victoza result. The Mounjaro page presented SURMOUNT-1, the obesity trial behind Zepbound, as a Mounjaro result. The Mounjaro and Zepbound pages said to discard a pen 21 days after first use; single-dose pens are used once, and 21 days is the total time one may spend out of the refrigerator. From September 16 to 17 the Ozempic page's storage card showed Wegovy's single-dose pen rules instead of Ozempic's 56-day in-use rule.
Correction: Victoza and Mounjaro pages now show their own label dosing and approved uses and make no weight-loss claim; storage cards follow each label, and every brand's dose ladder comes from its own label.
Reported by: GLP1Zoom editorial audit
Side-effect rates → Error: The Mounjaro pages showed side-effect rates from SURMOUNT-1, an obesity trial, instead of the diabetes trials in Mounjaro's label (nausea 31% instead of 18% at 15 mg). The Victoza pages showed Saxenda's rates (nausea 39% instead of 20%). Saxenda listed an 11% rate for decreased appetite that its label does not report, and several placebo figures for Wegovy, Ozempic, Rybelsus and Saxenda did not match their labels.
Correction: Each drug's side-effect rates now come from the placebo-controlled table in its own FDA label, and the pages name the table and dose they were read from.
Reported by: GLP1Zoom editorial audit
Coupon and without-insurance pages → Error: These pages listed compounded versions at $150-$400 a month for Trulicity, Victoza and Byetta, which have none; said the manufacturer copay card is the biggest saving on Saxenda, whose card closed in 2023, and on discontinued Byetta; described manufacturer cash programs as limited to early titration doses, which NovoCare and LillyDirect are not; and gave an income threshold, discount-card savings of 10-40% and a count of "12+ verified partners" that we could not source.
Correction: Each page now lists only the routes that exist for its drug, with that drug's own card terms, closure notice or self-pay price.
Reported by: GLP1Zoom editorial audit
Cost pages → Error: After the savings-card prose was corrected, the Wegovy page and the Wegovy cost table still showed the card as "as low as $0" (the card's floor is $25), the compounded semaglutide and tirzepatide cost tables could show a manufacturer card that does not exist, the Rybelsus card was listed at $10 instead of $25, and Trulicity's card was missing. Cost pages also quoted copay tiers of $25-$75 and $100-$300 and a $199-$899 telehealth range that we could not source, and listed Rite Aid among retail pharmacies.
Correction: Card amounts now match the manufacturers' terms, compounded products show no card, and the unsourced ranges and the retail list were removed. Each cost page now gives the drug's own card terms and self-pay basis instead.
Reported by: GLP1Zoom editorial audit
How-it-works pages → Error: The compounded semaglutide and compounded tirzepatide pages said the product was formulated to the FDA-approved specification; compounded products are not FDA-approved. Every how-it-works page said the drug lasts days, which is not true of Byetta (a half-life of about 2.4 hours).
Correction: Compounded pages now say the product is not FDA-approved and is not reviewed by the FDA for safety, effectiveness or quality. Each page states its own drug's half-life and the uses its FDA label approves.
Reported by: GLP1Zoom editorial audit
Wegovy storage → Error: The Wegovy storage page and the storage card on the Wegovy page said a Wegovy pen keeps 56 days at room temperature after first use. That applies only to the four-dose FlexTouch pen; a single-dose pen or syringe may be kept out of the refrigerator for up to 28 days, before its cap is removed.
Correction: Both pages now give each presentation its own limit from the June 2026 label. The Victoza, Byetta and Bydureon BCise storage pages now quote their labels as well.
Reported by: GLP1Zoom editorial audit
Side-effect pages → Error: The Trulicity, Byetta and Bydureon BCise pages showed placeholder class-average rates as their own trial results ("nausea affected 35% of people on Trulicity against 12% on placebo"), with the source given as "class average". Every side-effect page listed suicidal thoughts as under FDA review, although in January 2026 the FDA reported no increased risk and asked for that warning to be removed from the Wegovy, Saxenda and Zepbound labels; the Byetta page described a boxed thyroid warning Byetta does not have; all pages advised taking the drug in the evening, including the Rybelsus tablet, which is taken in the morning. The Byetta and Bydureon BCise contraindications and the Bydureon BCise side-effect rates did not match their labels, and Saxenda listed pregnancy as a contraindication, which its current label does not.
Correction: Trulicity and Byetta now show the placebo-controlled rates from their labels; Bydureon BCise, whose trials had no placebo arm, shows its label's rates without a placebo comparison. Boxed-warning statements, contraindications and serious-risk lists follow each label, and the suicidality statements now describe the FDA's 2026 review.
Reported by: GLP1Zoom editorial audit
Dosage pages → Error: Several dosage surfaces contradicted the current FDA labels. Wegovy's maximum dose was given as 2.4 mg on the dosage chart, comparison and FAQ pages; the June 2026 label allows 7.2 mg for adults. The Saxenda, Victoza and Rybelsus pages said to take a missed daily dose as soon as remembered, and comparison tables gave Saxenda and Victoza a 12-hour rule; the labels say to skip it, and to restart Saxenda or Victoza at 0.6 mg after more than 3 days without a dose. Trulicity and Bydureon BCise missed-dose windows were counted from the missed day instead of from the next dose. The Trulicity, Byetta and Bydureon BCise dosage pages showed a placeholder schedule, and every dosage page, including the Rybelsus tablet page, told readers to turn a dose dial.
Correction: Dosage pages now take the doses, the maximum, the missed-dose rule, how to take or inject, overdose advice and kidney, liver and children's dosing from each drug's current FDA label, and name the label version they were checked against. A pre-deploy check now fails when a published maximum is not the label's.
Reported by: GLP1Zoom editorial audit
Oral GLP-1 pills → Error: A price guide and the Sesame review still gave oral Wegovy 4 mg at $149 a month after that introductory price ended on August 31, 2026. The oral GLP-1 page, the Foundayo page and the price guide listed Foundayo 2.5 mg and 5.5 mg at $199 and $299 a month.
Correction: Oral Wegovy is $149 a month at 1.5 mg, $199 at 4 mg and $299 at 9 mg and 25 mg. Through December 31, 2026 Lilly charges $149 for Foundayo 2.5 mg and $199 for 5.5 mg; 9 mg is $299.
Reported by: GLP1Zoom editorial audit
Manufacturer savings cards → Error: Several pages said the Wegovy Savings Card brings the copay to "as little as $0", one page gave the Ozempic card's limits as $150/$300/$450 per 1/2/3-month fill, the Zepbound card was described as saving up to $150 a month, and the Mounjaro card's annual limit was given as $1,800 with no mention of its separate price for patients whose plan does not cover Mounjaro.
Correction: From the manufacturers' current terms: Wegovy and Ozempic cards bring the copay to as little as $25 and pay up to $100/$200/$300 per 1/2/3-month fill; the Zepbound card pays up to $100 a month and $1,300 a year; the Mounjaro card pays up to $150 a month and $1,950 a year, and patients whose commercial plan does not cover Mounjaro can pay as low as $499 a month. A second pass the same day found the old figures still in the coupon listings, the Wegovy savings card page, the savings calculations and several cost pages (including a $225 Wegovy cap and a $1,800 Mounjaro annual cap) and corrected them; a build check now rejects them.
Reported by: GLP1Zoom editorial audit
Prices → Error: Mounjaro's list price was given as about $1,069 a month in 32 places and in the cost calculators. LifeMD's required membership was listed as $75 a month and its Zepbound price as $349. Offer cards for HealthRX showed "$165/mo on the 12-month plan", although the 12-month plan works out to $99 a month and $165 is the monthly plan.
Correction: Lilly lists Mounjaro at $1,112.16 per fill. LifeMD charges $149 a month after a $39 first month, and Zepbound starts at $299. HealthRX cards now describe $165 as the monthly Subscribe & Save price and name the $99 12-month plan separately.
Reported by: GLP1Zoom editorial audit
Victoza → Error: From July to September 2026, 35 files on this site said Victoza was discontinued in the US in April 2024, including a guide explaining why, and Victoza was removed from the type 2 diabetes options. That withdrawal was in the UK. In the US, FDA's NDC directory lists Victoza with no marketing end date, and FDA's drug shortage database lists it with limited availability.
Correction: Pages now describe Victoza as still sold in the US with limited supply, name generic liraglutide as the same medicine in the same doses, and list Victoza among the type 2 diabetes options again.
Reported by: GLP1Zoom editorial audit
GLP-1 drug shortages → Error: The shortage page listed Saxenda as resolved in May 2024, and a Saxenda FAQ said the same. FDA's drug shortage database has listed Saxenda since July 2023, and on August 25, 2026 it recorded that Saxenda will be discontinued in January 2027.
Correction: The shortage table now follows FDA's database as read on September 16, 2026, and Saxenda pages carry a notice about the January 2027 discontinuation.
Reported by: GLP1Zoom editorial audit
Eden review → Error: The review said FDA had "not yet directly warned" Eden as of June 2026. FDA issued Eden warning letter 728279 on June 8, 2026. Eden and Henry Meds reviews also said "30+" telehealth firms received FDA letters in March 2026; the letters we can verify are dated February 20, 2026, and the count could not be verified. The Henry Meds review said Trustpilot had flagged its profile for review manipulation, which we could not source.
Correction: The Eden review names the letter and its date; the count and the unsourced Trustpilot claim were removed; Eden's headline $99/month price now includes its required $99 membership.
Reported by: GLP1Zoom editorial audit
How we make money → Error: Several pages said "No pay-for-placement" and that commission "never affects rankings". Since August 7, 2026, partner offers have been listed first in rails marked Sponsored. /about said prices were "verified monthly with the partner" (we check each provider's published pages), counted "12+" providers and "263" interaction pages (10 and 169), and claimed 100% of clinical claims were sourced. A "click receipt" on /visit pages showed payout ranges for providers that pay us nothing.
Correction: Every page now says partner offers are listed first and marked Sponsored, and that payment never changes a score. The price-check wording matches what we do. The click receipt was removed.
Reported by: GLP1Zoom editorial audit
Drug pages → Error: Drug pages showed seven "patient transformations" with first names, ages, states, weights and quoted comments. They were composites built from clinical-trial averages, not real people, though a note under them said so.
Correction: Removed from every drug page.
Reported by: GLP1Zoom editorial audit
Cost pages → Error: The "cheapest partner price" used the medication price alone and left out required memberships. Wegovy showed $149/month when the lowest all-in monthly cost was $298.
Correction: The figure is now the all-in monthly cost: medication plus any required membership.
Reported by: GLP1Zoom editorial audit
Drug, cost and without-insurance pages → Error: 36 pages said "about half of states" cover GLP-1s under Medicaid.
Correction: KFF counts 13 of 50 states covering GLP-1s for obesity as of January 2026. All 36 pages now say 13.
Reported by: GLP1Zoom editorial audit
How-it-works pages → Error: The pages said every GLP-1 is made with recombinant DNA in yeast or bacteria, which is wrong for exenatide, which is synthetic, and for orforglipron, which is not a peptide. The Byetta page's answer on how long the drug stays in the body described other drugs.
Correction: Each page now describes its own molecule, including how it is made and its half-life.
Reported by: GLP1Zoom editorial audit
Medicaid coverage by state → Error: 22 of 50 state rows showed the wrong coverage level. Mississippi and Missouri were listed as not covering GLP-1s for weight management; both do.
Correction: Every row was re-derived from KFF's Medicaid GLP-1 tracker (13 states cover GLP-1s for obesity as of January 2026).
Reported by: GLP1Zoom editorial audit
Storage pages → Error: Every storage page said pens can stay out of the fridge for "about 21 to 56 days". The window depends on the drug; Trulicity's label allows 14 days.
Correction: Each page now gives the room-temperature window from its own drug's FDA label.
Reported by: GLP1Zoom editorial audit
PlushCare → Error: PlushCare was listed at $99/month, an outdated figure.
Correction: PlushCare prescribes but does not dispense medication. Its $19.99 monthly fee is separate, and the medication is billed by your pharmacy.
Reported by: GLP1Zoom editorial audit
Saxenda savings card → Error: Nine places, including the printable pharmacy card, said the Saxenda savings card could bring the cost to "as low as $25/month" through December 2026. Novo Nordisk closed the program to new enrollees on June 30, 2023.
Correction: The offer was removed everywhere. In the same review the Rybelsus copay was corrected from $10 to $25, and its monthly cap from $150 to $100 (effective January 2, 2026).
Reported by: GLP1Zoom editorial audit
Oral GLP-1 pills → Error: Foundayo's self-pay price was listed as "not yet published".
Correction: Lilly published it at launch: $149 to $299 a month depending on dose, or $349 for the top doses without a refill within 45 days.
Reported by: GLP1Zoom editorial audit
Hair loss pages → Error: A table cited the US Wegovy label for a hair-loss rate of about 5.3% vs 2.5% in people who lost more than 20% of body weight. That subgroup is not in the US label. Two other rates were credited to single trials; the labels report pooled data.
Correction: The row was removed, and the other rates now cite the pooled label data.
Reported by: GLP1Zoom editorial audit
Ozempic savings card → Error: The page listed per-fill savings caps of $150/$300/$450 and implied that people without coverage could still use the card.
Correction: Novo Nordisk's terms say $100/$200/$300, and the card does not apply without coverage; the self-pay price is $349/month.
Reported by: GLP1Zoom editorial audit
Protein guide → Error: The guide recommended 1.0–1.2 g of protein per pound of body weight (about 2.2–2.6 g/kg), a unit error, and cited a lean-mass figure no trial reported.
Correction: The guide now uses The Obesity Society's 2024 range for people on anti-obesity medication, 0.8–1.5 g/kg, and the lean-mass results from STEP-1 and SURMOUNT-1.
Reported by: GLP1Zoom editorial audit
State drug pages → Error: State pages said cash prices were averaged "across surveyed local pharmacies". We do not survey pharmacies.
Correction: The figures are now described as reference estimates from recent provider data.
Reported by: GLP1Zoom editorial audit
Compounded semaglutide and tirzepatide → Error: Pages for compounded versions showed brand trial results, such as 14.9% mean weight loss in STEP-1, as if they applied to compounded products, which were not studied in those trials.
Correction: Results are now attributed to the FDA-approved brand product, with a note that compounded versions were not tested.
Reported by: GLP1Zoom editorial audit
Type 2 diabetes → Error: Bydureon BCise was listed as a current treatment option. It was discontinued in the US in October 2024.
Correction: Removed from the options.
Reported by: GLP1Zoom editorial audit
Cost calculator → Error: The calculator could name a provider we do not recommend as the "lowest verified telehealth price", and five providers we do not recommend still had sign-up links.
Correction: Providers we do not recommend are excluded from the calculator and have no sign-up links.
Reported by: GLP1Zoom editorial audit
Video reviews → Error: The video page listed 20 videos that did not exist, with invented channel names and dates and two written transcripts.
Correction: All removed. The page stays empty and out of search results until it lists real videos.
Reported by: GLP1Zoom editorial audit
Cheapest provider guide → Error: The guide used $650/month for NovoCare self-pay Wegovy, a 2024 price.
Correction: Updated to about $349/month at maintenance doses ($199/month introductory).
Reported by: GLP1Zoom editorial audit
Editorial standards → Error: Home, about and drug pages named four medical reviewers (MD, PharmD, RD, JD) and said every drug page was reviewed by a US-licensed clinician. The reviewers were placeholders, not real people.
Correction: Removed. Pages now say the GLP1Zoom editorial team reviews content and that we have no clinicians on staff.
Reported by: GLP1Zoom editorial audit